Search Results

MC# 21-07
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with a MEK Inhibitor in Patients with Advanced or Metastatic Solid Tumors

MC# 16-39
Phase I Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas

MC# 19-05
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 20-09
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 20-14
A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combination of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/ or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

MC# 20-33
A Phase Ib/II, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR- 255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors

MC# 19-09
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

MC# 19-33
A Phase I, Open-label Single-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies

MC# 20-17
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies

MC# 20-19
A Phase I, Open-Label Multi-Dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), And The Effects Of A Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies

MC# 17-04
Phase I/II Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNb-NIS), Monotherapy and in Combination With Avelumab in Patients with Refractory Solid Tumors

MC# 19-12
Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

MC# 19-21
A Phase I/IIa Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

MC# 20-11
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors

MC# 18-26
A Phase I/II Study of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MC# 19-37
A Phase Ib, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

MC# 19-39
An Open Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 in Adult Patients with Metastatic Solid Tumors; A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study

MC# 18-17
A Phase I Study of RGX-202, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts

MC# 19-31
A Phase I, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab

MC# 15-03
A Phase I/II, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

MC# 19-25
A Phase I open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

MC# 20-06
A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors

MC# 20-16
An Open-Label, Multicenter, Phase IB/II Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors

MC# 20-18
An Open-Label, Multicenter, Phase II Basket Study to Evaluate the Efficacy and Safety of Lenvatinib (14 mg/m2) in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies (Pediatric Solid Tumor Basket Trial)

MC# 20-20
A Phase II Study of Futibatinib in Patients with Specific FGFR Aberrations